琥珀酸美托洛尔缓释片联合曲美他嗪治疗冠心病心力衰竭的临床效果  

Clinical Effect of Metoprolol Succinate Sustained Release Tablets Combined with Trimetazidine in the Treatment of Coronary Heart Disease and Heart Failure

作　　者：甄惠俊 陈盛开 林子川 Zhen Huijun;Chen Shengkai;Lin Zichuan(First Department of Cardiovascular,Taishan People's Hospital,Taishan 529200,Guangdong Province,China)

机构地区：[1]台山市人民医院心血管一科,广东台山529200

出　　处：《中外医药研究》2023年第32期51-53,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:观察采用琥珀酸美托洛尔缓释片联合曲美他嗪综合治疗冠心病心力衰竭患者的临床效果。方法:选取2020年11月—2022年11月台山市人民医院收治的冠心病心力衰竭患者90例为研究对象,按照随机数字表法分为对照组和观察组,各45例。对照组单纯应用琥珀酸美托洛尔缓释片治疗,观察组在对照组基础上给予曲美他嗪治疗。比较两组治疗效果、心功能指标及6分钟步行试验(6MWT)距离、不良反应发生情况。结果:观察组治疗效果总有效率高于对照组,差异有统计学意义(P=0.026)。治疗后,两组左室射血分数、6MWT距离高于治疗前,观察组高于对照组,左室舒张末期内径、左室收缩末期内径水平低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:琥珀酸美托洛尔缓释片联合曲美他嗪治疗冠心病心力衰竭患者的临床效果显著,可改善患者的心功能及运动耐力,不会增加患者不良反应发生率。Objective:To observe the clinical effect of metoprolol succinate sustained release tablets combined with trimetazidine in patients with coronary heart disease and hear failure.Methods:A total of ninety patients with coronary heart disease and heart failure admitted to Taishan People's Hospital from November 2020 to November 2022 were selected as the study objects,and were divided into control group and observation group according to random number table method,with forty-five cases in each group.The control group was treated with metoprolol succinate sustained release tablets alone,and the observation group was treated with trimetazidine on the basis of the control group.The therapeutic effect,cardiac function index,6-minute walking test(6MWT)distance and adverse reactions were compared between the two groups.Results:The total effective rate of therapeutic effect of the observation group was higher than that of the control group,the difference was statistically significant(P=0.026).After treatment,left ventricular ejection fraction and 6MWT distance of the two groups were higher than those before treatment,and the observation group was higher than control group,the left ventricular end-diastolic diameter and left ventricular end-systolic diameter were lower than before treatment,and the observation group was lower than control group,with statistical significance(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Metoprolol succinate sustained release tablets combined with trimetazidine in the treatment of coronary heart disease patients with heart failure has significant clinical effect,can improve the patients'heart function and exercise endurance,and will not increase the incidence of adverse reactions.

关 键 词：冠心病 心力衰竭 琥珀酸美托洛尔 曲美他嗪 心功能 

分 类 号：R54[医药卫生—心血管疾病]